MediWound (NASDAQ:MDWD – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
46.8% of MediWound shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for MediWound and Taysha Gene Therapies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 1 | 1 | 4 | 0 | 2.50 |
| Taysha Gene Therapies | 1 | 0 | 12 | 2 | 3.00 |
MediWound presently has a consensus price target of $33.00, suggesting a potential upside of 170.27%. Taysha Gene Therapies has a consensus price target of $12.77, suggesting a potential upside of 242.34%. Given Taysha Gene Therapies’ stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than MediWound.
Valuation & Earnings
This table compares MediWound and Taysha Gene Therapies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediWound | $11.86 million | 13.23 | -$23.88 million | ($1.80) | -6.78 |
| Taysha Gene Therapies | $9.77 million | 124.40 | -$109.00 million | ($0.42) | -8.88 |
MediWound has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
MediWound has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Profitability
This table compares MediWound and Taysha Gene Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -170.10% | -47.24% | -24.27% |
| Taysha Gene Therapies | N/A | -56.19% | -41.84% |
Summary
Taysha Gene Therapies beats MediWound on 9 of the 15 factors compared between the two stocks.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
